Latitude Advisors, LLC Cel Sci Corp Transaction History

Latitude Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 28, 2022	SELL	$2.58 - $4.99 $83,437 - $161,376	-32,340 Reduced 66.67%	16,170 $73,000
Q1 2022 Apr 29, 2022	BUY	$3.93 - $7.7 $63,548 - $124,509	16,170 Added 50.0%	48,510 $191,000
Q3 2021 Oct 14, 2021	BUY	$7.64 - $12.49 $123,538 - $201,963	16,170 Added 100.0%	32,340 $355,000
Q2 2021 Jul 20, 2021	BUY	$8.68 - $27.49 $9,548 - $30,239	1,100 Added 7.3%	16,170 $140,000
Q1 2021 Apr 14, 2021	BUY	$12.0 - $27.64 $60,840 - $140,134	5,070 Added 50.7%	15,070 $235,000
Q4 2020 Feb 04, 2021	BUY	$11.05 - $16.62 $110,500 - $166,200	10,000 New	10,000 $117,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Latitude Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Latitude Advisors, LLC with notifications on news.